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Abstract
Over the past two decades, healthcare-associated exposure has increasingly been proved to be a 
means of hepatitis C virus (HCV) transmission, especially in hemodialysis units. The prevalence 
of HCV among hemodialysis patients is known to be several times greater than that of the general 
population of the United States and chronic HCV infection is associated with significant morbidity 
and mortality among these patients. During 2008–2011, HCV infection outbreaks were identified 
in multiple US hemodialysis facilities, resulting in at least 46 new HCV infections among 
hemodialysis patients. These outbreaks, linked to infection control breaches, also highlight the 
failure of some facilities to follow established guidelines for routine HCV antibody (anti-HCV) 
screening and response to new HCV infection among hemodialysis patients. Current national 
guidelines recommend screening of hemodialysis patients for anti-HCV on facility admission and, 
for susceptible patients, on a semiannual basis.
Here, we seek to underscore the importance of compliance with national recommendations for 
anti-HCV screening of hemodialysis patients and actions to be taken in the event of possible HCV 
transmission within a hemodialysis facility. These include general steps to ensure that: 
hemodialysis patients are routinely screened for anti-HCV to facilitate early detection of new 
infections; newly infected patients are informed of the change in their HCV status and undergo 
clinical evaluation; and public health officials are notified of new HCV infections in a timely 
manner. We then focus on the need to assess infection control practices at the facility, with 
particular attention given to safe handling of injectable medications, hand hygiene and disinfection 
practices.
In the absence of a vaccine, routine screening and adherence to standard infection control practices 
will remain the key strategies for preventing HCV transmission in hemodialysis units.
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Background
Hepatitis C virus (HCV) infection affects an estimated 2.7–3.9 million persons (1.0–1.5%) 
in the United States (1) and is associated with potentially serious health consequences, 
including liver cirrhosis and hepatocellular carcinoma (2). Identifying new HCV infections 
is often difficult, as most newly-infected patients tend to be asymptomatic (2–4). The risk of 
acquiring HCV infection is known to be high among injection-drug users (3, 4), since the 
virus is transmitted efficiently through intravenous exposure (5). However, healthcare-
associated exposure has increasingly been linked to HCV transmission over the past two 
decades in the United States (6). Transmission of HCV in a variety of healthcare settings, 
including hemodialysis units, has been well documented (7–10).
Maintenance hemodialysis patients can be at increased risk of exposure to bloodborne 
pathogens, such as HCV, in the course of receiving treatment owing to several factors, 
including the need for repeated and prolonged access to the bloodstream and concurrent 
treatment of multiple patients in the same area. The prevalence of HCV among US 
hemodialysis patients (approximately 8–10%) (11–13) is also known to be several times 
higher than the general US population (1). Several outbreaks of HCV have occurred in 
hemodialysis units across the US, triggering notification of hundreds of patients. Of 13 
healthcare-associated HCV outbreaks in the United States during 2008–2011 that were 
reported to the United States Centers for Disease Control and Prevention (CDC), five 
(38.5%) occurred in hemodialysis facilities, with 46 new HCV infections documented (14). 
While the exact mechanism of HCV transmission could not be ascertained in each facility 
where an outbreak occurred, several breaches in infection control practices, particularly 
improper injection-medication practices and suboptimal cleaning and disinfection, were 
identified. Investigations using molecular analysis of the viruses from affected patients, 
together with epidemiologic data, have demonstrated the spread of infection among patients 
treated in the same facility (15). These findings indicate that despite the availability of 
prevention guidelines (16), HCV transmission among patients receiving hemodialysis 
remains a problem. In the course of investigating outbreaks, some of the affected facilities 
were noted to be non-adherent with established guidelines for screening and managing 
hemodialysis patients for new HCV infection (17, 18). Because most new HCV infections 
are asymptomatic (2–4), routine screening of hemodialysis patients is crucial for the prompt 
identification of new infections and outbreaks among these patients.
CDC has developed and disseminated recommendations addressing practices to help prevent 
the transmission of bloodborne pathogens and bacterial infections in hemodialysis units 
(16). With respect to the detection of HCV transmission, routine screening of hemodialysis 
patients for antibody to HCV (anti-HCV) is recommended on facility entry (at the time of 
first admission), and subsequently, for anti-HCV susceptible patients, on a semiannual basis. 
The guidelines also recommend monthly alanine transaminase (ALT) testing for 
Mbaeyi and Thompson Page 2













hemodialysis patients, to facilitate early detection of new HCV infections and assist in 
understanding the likely period of exposure. ALT elevations occur in a majority of new 
HCV infections and often precede HCV seroconversion (19–24). Routine HCV antibody 
screening for hemodialysis patients is also recommended by Kidney Disease Improving 
Global Outcomes (KDIGO) (25), and is included in the Department of Health and Human 
Services National Action Plan to Prevent Healthcare-Associated Infections (HAI) (26), 
which identifies HCV screening as a priority recommendation for advancing the prevention 
of healthcare-associated infections in end-stage renal disease facilities.
This paper outlines steps that should be taken by hemodialysis facilities to 1) ensure that 
new HCV infections are not occurring among patients receiving treatment within the 
hemodialysis unit; 2) detect new infections, if they occur, and manage patients in a timely 
manner; and 3) forestall or interrupt potential intra-facility transmission of the virus. The 
actions to be taken include identification of both acute hepatitis C infection (i.e., persons 
with signs and symptoms of inflammation of the liver, such as jaundice, nausea, anorexia 
and fever, often accompanied by elevated liver enzyme levels) and HCV seroconversion 
(i.e., identified change in serologic status from anti-HCV negative to positive, with or 
without symptoms of acute hepatitis C infection) among patients. Specific guidance is also 
provided on how to manage HCV screening results and assess infection control practices in 
the context of possible HCV transmission within the facility.
Managing Hepatitis C Virus Seroconversions
General Steps (Figure 1)
All hemodialysis facilities should establish a policy for screening patients for anti-HCV. 
Screening should occur on facility admission and subsequently, for HCV susceptible 
patients, on a semiannual basis. The intent of this practice is to establish each patient’s 
baseline anti-HCV status (i.e., at the time of first entry to the facility), and by routinely 
comparing susceptible patients’ baseline status to the results of their semiannual HCV 
screening, help providers to identify if an HCV seroconversion (i.e., a new HCV infection) 
occurs. In addition, patients should undergo monthly screening for serum ALT levels (16). 
The presence of symptoms consistent with acute hepatitis C infection or an unexplained 
elevation in ALT level should prompt HCV testing (27), whether or not six months have 
passed since the patient’s last anti-HCV test.
Patients who are anti-HCV positive on facility admission (based on admission testing, 
known history of infection, or documentation of prior positive test result) should be 
considered already infected, i.e., non-susceptible, and do not require continued routine anti-
HCV screening. However, such patients should be evaluated and managed by appropriate 
clinical specialists. In the event that an HCV seroconversion or acute hepatitis C infection is 
identified in a previously susceptible patient (i.e., a patient who was anti-HCV negative on 
facility entry), the following steps should be taken:
Confirm HCV Status—The first step should be to confirm that the positive anti-HCV test 
result represents a new HCV infection. To accomplish this, all previous anti-HCV screening 
records for the patient should be reviewed to ensure there was no previously documented 
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positive test result. In the event that there was no previous positive anti-HCV test result for 
the patient, i.e., this represents the first known positive anti-HCV test result, the patient 
should then undergo supplemental laboratory testing using a more specific test such as 
nucleic acid testing, i.e., polymerase chain reaction (PCR), and/or recombinant immunoblot 
assay (RIBA) to prevent reporting of a false-positive result (16, 28). If the supplemental test 
is positive, the patient should be considered infected with HCV. If the supplemental test is 
negative, then the anti-HCV positive test results should be considered a false-positive and 
the patient considered uninfected and susceptible to HCV infection. Routine anti-HCV 
screening should continue for such a patient on a semiannual basis (16). If the supplemental 
test is indeterminate, then the presence of a new HCV infection in such a patient cannot be 
established. In such cases, additional testing as well as monitoring of the patient’s liver 
enzymes (i.e., serum ALT) should be performed (28, 29).
In making a determination of which supplemental test to use, facilities should note that in 
recent years RIBA has been available on a limited basis, and nucleic acid testing, i.e., PCR, 
is now widely available and routinely used to confirm current viremia in infected patients 
(3). Because only a small proportion of hemodialysis patients have viremia in the absence of 
antibodies (12), it is not necessary to screen all patients initially with a nucleic acid test. A 
table to aid with the interpretation of HCV screening results has been developed by CDC 
(28), and is subject to updates to reflect changing testing practices and test availability.
Inform the Patient and Arrange for Clinical Evaluation—Owing to the benefits of 
preventive services and early clinical intervention (30), as well as the related morbidity and 
mortality associated with HCV infection in persons with renal disease (3, 30), a clinician 
from the hemodialysis facility should inform the patient if they have been found to have 
HCV infection. The patient should undergo clinical evaluation by an appropriate medical 
specialist (e.g., hepatologist, infectious disease specialist) for lifestyle counseling, 
monitoring, and possible treatment (3). Prompt identification of new HCV infection, referral 
to care, and early treatment – where indicated – have been shown to improve patient 
outcomes (30–33).
Report the Case(s) to the Health Department—Once a new, confirmed HCV 
infection at a hemodialysis facility has been identified, it should be promptly reported to the 
local or state health department (29). The Council of State and Territorial Epidemiologists 
(CSTE) recommends that healthcare providers and institutions report all cases of acute 
hepatitis C infection to public health authorities to facilitate disease surveillance and 
outbreak detection (34). Moreover, many states have laws requiring the reporting of 
outbreaks to public health authorities and reporting of viral hepatitis seroconversions to 
public health authorities is required by regulation as outlined in the Centers for Medicare & 
Medicaid Services ESRD Program Interpretative Guidance (35). Facilities reporting new 
HCV infections should also be aware that reporting such infections does not necessarily 
imply healthcare-associated transmission of the virus, but the practice offers the opportunity 
to receive the assistance of public health experts in evaluating the possibility of such 
transmission as well as establishing the presence of additional patient risk factors for HCV 
infection. Health departments help to: establish the patient’s past HCV testing history 
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through review of public health surveillance records and hepatitis registry data; provide 
expertise in conducting patient interviews to identify the presence of other potential 
healthcare exposures or behavioral risk factors for HCV infection; initiate necessary 
epidemiologic investigations; and provide guidance and expertise on assessing infection 
control practices at the facility.
If public health evaluation of newly infected patients rules out behavioral risk factors and 
other opportunities for HCV exposure outside the dialysis facility, the possibility of 
healthcare-associated transmission should be given strong consideration. This is particularly 
important when infection control breaches are identified at the facility (as outlined in the 
following section) or when more than one new HCV infection is identified in a facility. In 
these instances, other at-risk patients at the facility should be notified and counseled on the 
need for testing (36).
Assess Infection Control Practices at the Facility—When one or more new HCV 
infections are identified, evaluating the potential for HCV transmission within the facility is 
important. A thorough infection control assessment should be conducted. Infection control 
remains the primary strategy for prevention of healthcare-associated HCV transmission and 
isolation of HCV-positive patients is not recommended in hemodialysis units (16).
The infection control assessment could be conducted by an infection preventionist in an 
affiliated hospital or a hemodialysis facility staff member with expertise in infection control. 
The latter could be a registered nurse (RN) with infection control training, in line with the 
proposal contained in the CMS Conditions for Coverage for End-Stage Renal Disease 
Facilities (37). If the facility does not have access to healthcare personnel with the proper 
training or certification, an infection preventionist could be hired on a consultant basis. The 
health department can be a resource to help in identifying such individuals and should also 
have the opportunity to guide or participate in infection control assessments in the setting of 
possible transmission.
Outlined below are the steps to be taken when conducting an infection control assessment in 
the context of identifying one or more patients with new HCV infection at the facility. These 
steps should also be undertaken routinely; for example, to coincide with periods when 
semiannual anti-HCV screening is conducted for patients at the facility, even in the absence 
of new HCV infection, to ensure ongoing compliance with best practices for infection 
control and prevention. When infection control breaches are noted, a plan of correction and 
a system for ensuring compliance with the plan should be developed within the dialysis unit. 
This might include educating staff to reinforce proper practices.
CDC has developed a free continuing education course on infection prevention that might be 
a helpful resource (38). The one-hour self-guided course is targeted at outpatient 
hemodialysis healthcare personnel, including nurses and technicians, and addresses basic 
infection control concepts and recommendations, such as medication safety and hand 
hygiene practices.
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Infection Control Assessment (Figure 2)
Medication Preparation and Administration—Transmission of bloodborne viruses 
and other pathogens has occurred in a variety of healthcare settings, including hemodialysis 
units, when healthcare personnel have failed to use aseptic technique and follow safe 
injection practices when preparing and administering parenteral medications. Improper 
medication practices have been identified as an independent risk factor for increased HCV 
prevalence in hemodialysis facilities (12). Unsafe practices that have resulted in HCV 
transmission in healthcare settings include: preparing medications in contaminated areas, 
using the same syringe to administer medication to more than one patient, and reusing a 
syringe to access a medication container and then using leftover contents from that container 
for additional patients (6).
Prepare Medications in a Clean Area Designated for Parenteral Medication 
Preparation and Storage: To minimize the risk of intra-facility transmission of HCV and 
other bloodborne pathogens, a clean area should be designated for parenteral medication 
preparation and storage (16). (The term “medications” should be interpreted to include 
intravenous fluids and saline flushes.) This area should be clearly delineated from all 
potentially contaminated areas and equipment in the dialysis unit and should be 
appropriately organized for the purpose of medication preparation (i.e., having bins of 
sterile, individually wrapped syringes and needles at hand, along with appropriate waste 
containers for needles and syringes). Medications should not be kept or prepared at the 
dialysis station as this is considered a contaminated area. Preferably, a separate clean room 
should be designated and used for medication preparation and storage, as this constitutes the 
safest approach with lowest likelihood of cross-contamination during medication 
preparation.
Once medications have been drawn, they should be delivered to each individual patient 
station separately. Mobile medication carts should not be used to deliver medications to 
patient stations, nor should medications move from one station to another, as this has been 
associated with HCV transmission in dialysis units (12, 15).
Use a Sterile Syringe and Sterile Needle for Each Injection and Each Entry into a 
Medication Container: Needles and syringes are sterile items intended for single use. A 
sterile needle and sterile syringe should be used for each injection and each entry into a 
medication container. Reuse of needles and syringes either for more than one patient or to 
reenter a medication container constitutes an improper and dangerous medication practice, 
which has been linked to the transmission of bloodborne pathogens, including HCV (39, 
40).
While the danger associated with reusing needles is often easy to appreciate, several 
healthcare providers still underestimate the risk of bloodborne pathogen transmission 
associated with reusing syringes (6, 39). Contamination of syringes – after their use to 
administer a medication – has been well demonstrated, and the risk of backflow of blood 
and contamination of the syringe remains present even with the use of intervening lengths of 
IV tubing or valves (between the injection port and the patient) (6, 41). Changing the needle 
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or maintaining positive pressure on the syringe plunger do not protect against contamination 
of the syringe (6). In the event that a contaminated syringe is used to access a medication 
container, the container also becomes contaminated and this could lead to the transmission 
of infections to a large number of patients if contents of that container are used for 
additional patients (42).
To assess compliance with safe injection practices, staff should be directly observed when 
preparing and administering medications using a standardized assessment tool (43, 44). 
Unsafe practices should be immediately corrected. Further, reuse of syringes, either for more 
than one patient or to access shared medications, should be reported immediately to public 
health authorities as this unsafe practice should result in notification and bloodborne-
pathogen testing of potentially exposed patients.
Hand Hygiene Compliance and Glove Use—Bloodborne pathogens and other 
microorganisms may be transmitted directly from the hands of healthcare personnel to 
patients, or indirectly from patient to patient through the hands of healthcare personnel, if 
hand hygiene is not performed or is not done using the proper technique (45, 46). Hand 
hygiene refers to activities, such as handwashing, the use of an alcohol-based hand rub, and 
surgical antisepsis, which are intended to remove microorganisms from the hands (47).
Several improper practices have been noted among healthcare personnel with respect to 
hand hygiene and glove use. Healthcare personnel sometimes fail to perform hand hygiene 
before performing procedures such as preparation or administration of parenteral 
medications (48). Others have been observed wearing a fresh pair of gloves without 
performing hand hygiene after removal of used gloves, caring for more than one patient 
while wearing the same pair of gloves, or accessing clean supplies with contaminated gloves 
(15, 17). All the aforementioned practices increase the potential for disease transmission and 
should be corrected if observed during an infection control assessment.
Due to the inherent potential for exposure to blood and body fluids in dialysis units, 
healthcare personnel are required to wear gloves during routine patient-care activities at the 
dialysis station (16). The gloves are intended to provide protection for healthcare personnel; 
they are not intended as a substitute for proper hand hygiene. Hand hygiene should be 
performed whenever contact with the patient or with individual surfaces at the treatment 
station is anticipated. Also, hand hygiene should be performed after gloves are removed. 
Inadvertent contact with body fluids and just before performing an aseptic procedure are 
other examples of when hand hygiene is indicated (49).
In addition to audits performed during an assessment of suspected HCV transmission, 
hemodialysis facilities should routinely monitor staff adherence to proper hand hygiene and 
glove changing practices by performing hand hygiene and glove-use audits at least monthly. 
When performed, audits should be conducted in a way that directly measures compliance 
among individual healthcare workers whenever hand hygiene is indicated over a specified 
time period (47, 50). For example, a two-hour audit could be performed on the main 
treatment floor of the dialysis unit to assess hand hygiene compliance levels among 
healthcare personnel before and after performing procedures on patients. Such an audit will 
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quantify the total number of times hand hygiene is properly performed over the number of 
times it was indicated in the course of carrying out patient-care activities (50). Similar 
methods could be used to assess glove use practices amongst healthcare personnel (50, 51). 
The services of an external auditor, such as a certified infection preventionist, could be 
solicited to carry out the audit. Audits should be performed at different times of the day, 
across shifts and during changeover periods. In the setting of potential HCV transmission, 
special attention should be paid to lapses in hand hygiene occurring between periods of 
caring for different patients and working at different patient stations (e.g., healthcare 
personnel fails to perform hand hygiene after direct contact with a patent or surfaces at that 
patient’s treatment station and prior to direct contact with another patient).
Environmental Cleaning and Disinfection Practices—HCV is capable of surviving 
in the environment and remaining viable for at least 16 hours (52) and has been isolated 
from contaminated surfaces and equipment in healthcare settings (53, 54). Therefore, 
suboptimal surface cleaning and disinfection in healthcare settings could result in 
transmission of HCV (15). Cleaning and disinfection involves not only surfaces within the 
environment, but also shared medical equipment, such as blood glucose meters and blood 
pressure cuffs. Surfaces and equipment should be considered contaminated following use or 
once they have come into contact with a patient, even in the absence of visible blood or 
soiling. It is a common misconception that surfaces or equipment are not contaminated when 
there is no visible blood or soiling. Microscopic quantities of blood or other traces of 
contamination may be sufficient to transmit infections.
To create a safe environment for providing patient care, all hemodialysis units should be 
cleaned and disinfected using recommended agents. All surfaces in the dialysis station 
should be routinely disinfected after a patient receives treatment and before commencing 
treatment for a new patient. To facilitate thorough cleaning and disinfection and reduce the 
opportunity for cross-contamination, healthcare personnel should ensure that the patient who 
has just received treatment has left the dialysis station before commencing routine 
disinfection of that station. Several HCV outbreaks have shown an epidemiologic link 
between incident and prevalent HCV cases who received treatment on sequential shifts at 
the same dialysis station or treatment section. This observation highlights the role of proper 
disinfection of the station during station turnover to prevent the transmission of bloodborne 
pathogens in dialysis units. Whenever feasible, there should be a distinct shift changeover 
period (i.e., separation in patient treatment shifts) devoted to cleaning and disinfection 
activities, as well as preparing the dialysis stations for patients on the next shift (15). 
Disinfection should be performed using an EPA-registered hospital disinfectant (55) at the 
dilution specified by the manufacturer. A single step involving mechanical wiping is 
sufficient for routine disinfection of surfaces, except in the event of visible soil. When there 
is visible soil, a cleaning step (which may occur in multiple phases, depending on the 
amount of soil), should precede disinfection of surfaces. Shared equipment, such as blood 
glucose meters and blood pressure cuffs, should be cleaned and disinfected between each 
patient use, following the manufacturer’s instructions.
To help ensure compliance with recommended practices, the facility should have in place 
written protocols that delineate clinical and housekeeping staff roles and responsibilities 
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with respect to cleaning and disinfection of the environment. This should include guidance 
for how clinical staff should manage blood spills.
To assess compliance of environmental cleaning and disinfection practices with 
recommended guidelines, a staff member at the dialysis facility with certification in 
infection control should observe cleaning and disinfection practices on the treatment floor. 
The staff member should be attentive to all the steps involved in the process and ensure that 
the proper agents and techniques are employed in the process. In particular, attention should 
be devoted to observing the rinsing/wiping and drying of external surfaces of the dialysis 
machine and priming buckets between treatment sessions, to ensure that all surfaces are 
adequately cleaned and disinfected. It is preferable for bleeding patients onto the dialysis 
machine to not be practiced, as it can lead to blood-contamination of priming buckets. In the 
setting of suspected HCV transmission, pay particular attention to hurried station turnover 
procedures or other processes that could facilitate cross-contamination or incomplete 
disinfection of surfaces at the treatment station. The CDC has developed an environmental 
disinfection checklist to help facilitate assessment of facility cleaning and disinfection 
practices (56).
Multiple HCV Seroconversions
Healthcare-associated transmission of HCV – even in the event of a single confirmed case – 
constitutes an urgent public health situation, which should be thoroughly investigated and 
appropriately responded to (6, 16, 39), using the steps outlined above. Identification of 
multiple (i.e., two or more) new HCV infections at the same dialysis facility may represent 
ongoing transmission or signal a wider breach in infection control practices. For example, in 
2008, three new HCV seroconversions occurring within weeks of each other were identified 
in a hemodialysis unit in New York (18). Further investigation of patients with HCV 
infection at the facility revealed there were six additional patients with HCV 
seroconversions that occurred at the facility from 2001 to 2008. HCV infection in four 
patients was subsequently linked by epidemiologic and laboratory investigation to 
previously infected patients at the same facility. Numerous infection control breaches were 
noted at the facility during the response to the outbreak, including failures to implement 
routine HCV screening and review of results. This example illustrates prolonged patient-to-
patient transmission of HCV resulting from the facility’s failure to review and act on HCV 
screening test results in real time.
Due to the potential for ongoing transmission and risks to patient safety, additional steps are 
recommended for detection when more than one new HCV infection occurs within a dialysis 
facility. In such instances, the frequency of anti-HCV screening should be increased (e.g., 
implement monthly or quarterly screening) until no new infections have been identified for a 
period of six months (one full incubation period) (16). Aggressive infection control practices 
and ongoing monitoring of adherence should also be instituted in such facilities. These 
decisions should be made in consultation with public health authorities.
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Hemodialysis patients bear a substantial healthcare burden by virtue of having 
comorbidities, immunosuppression and the need for regular invasive treatment procedures. 
Healthcare providers should make every effort to ensure that no additional burden, in the 
form of preventable infections, is imposed on these patients as a consequence of receiving 
care. Hemodialysis facilities need to ensure that all necessary measures are taken to protect 
patients from acquiring infections such as HCV in the course of receiving treatment. To 
accomplish this, facilities should ensure that they adhere to CDC’s existing guidelines and 
recommendations for the prevention of healthcare-associated infections among hemodialysis 
patients. Specific attention should be focused on ensuring compliance with recommended 
anti-HCV screening policies and standard infection control practices. The HCV status of 
every dialysis patient at the time they are admitted to a facility should be known, and 
subsequent routine screening is needed to identify changes in serologic status. Such 
measures will facilitate early detection of new HCV infections and ensure prompt 
intervention. If patients with new HCV infection are identified, notification of public health 
authorities, who can assist with evaluating the potential for HCV transmission, is warranted. 
Infection control assessments, performed in conjunction with public health authorities, to 
identify practices known to be related to HCV transmission should specifically focus on a) 
medication preparation and administration, b) hand hygiene and glove use, and c) 
environmental cleaning and disinfection practices. There is no vaccine at present to prevent 
HCV infection; hence, there is a strong need to establish a program of staff infection 
prevention and control education and consistently reinforce proper infection control 
practices.
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Box 1: Best Practices in Preventing Healthcare-Associated Transmission of 
Hepatitis C Virus (HCV) in Hemodialysis Units
Practices for Detecting HCV Infection
• Screen all patients for possible HCV infection (anti-HCV antibody testing) on 
facility admission
• For susceptible patients, perform anti-HCV antibody testing semiannually and 
serumalanine transaminase (ALT) testing monthly
• Inform newly infected patients of the change in their HCV status and arrange for 
clinical evaluation/management
• Report new HCV infections to the local health department in a timely manner
Infection Control Practices
• Designate a separate clean area for medication preparation and storage
• Do not prepare medications at the dialysis station or in areas of the treatment 
floor that have potential to become contaminated
• Do not deliver medications to patient stations in mobile carts
• Ensure that a new needle and syringe is used for each injection and entry into a 
medication container
• Perform hand hygiene before and after contact with patients and prior to 
performing procedures
• Ensure that gloves are changed and hand hygiene is performed when moving 
from one patient to the next and before accessing clean supplies
• Disinfect each dialysis station after patient treatment is completed and before 
seating the next patient
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Algorithm for Managing Hepatitis C Virus Screening Results and Cases In Hemodialysis 
Facilities
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Guidance on Assessing Key Infection Control Practices in the Setting of Possible HCV 
Transmission in a Hemodialysis Unit
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